Old Web
English
Sign In
Acemap
>
authorDetail
>
Carole Schuhler
Carole Schuhler
Volume of distribution
Pharmacology
Bruton's tyrosine kinase
Pharmacokinetics
CD63
2
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
2021
Clinical and Translational Science
Martin Kaul
Peter End
Maciej Cabanski
Carole Schuhler
Annamaria Jakab
Magdalena Kistowska
Arvind Kinhikar
Alessio Maiolica
Angela Sinn
Rainard Fuhr
Bruno Cenni
Show All
Source
Cite
Save
Citations (2)
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
2021
Clinical and Translational Science
Felix Huth
Hilmar Schiller
Yi Jin
Birk Poller
Carole Schuhler
Wendy Weis
Ralph Woessner
Anton Drollmann
Peter End
Show All
Source
Cite
Save
Citations (0)
1